Evaluation of the new marker interleukin - 33 in Iraqi female patients with hyperthyroidism.
暂无分享,去创建一个
[1] D. Ye,et al. IL-33 , 2012, Journal of Investigative Medicine.
[2] E. Martı́n-Mola,et al. Frequency of Th17 CD4+ T Cells in Early Rheumatoid Arthritis: A Marker of Anti-CCP Seropositivity , 2012, PloS one.
[3] J. Devière,et al. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice. , 2012, The American journal of pathology.
[4] M. Steinhoff,et al. IL-33: a novel danger signal system in atopic dermatitis. , 2012, The Journal of investigative dermatology.
[5] A. Sachan,et al. Bone disease in thyrotoxicosis , 2012, The Indian journal of medical research.
[6] N. Viner,et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects , 2011, Arthritis research & therapy.
[7] Inbal Goshen,et al. Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling , 2011, Brain, Behavior, and Immunity.
[8] Xia Li,et al. IL-33: a promising therapeutic target for rheumatoid arthritis? , 2011, Expert opinion on therapeutic targets.
[9] Ashley M. Miller,et al. IL-33 Reduces Macrophage Foam Cell Formation , 2010, The Journal of Immunology.
[10] I. McInnes,et al. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases , 2009, Arthritis research & therapy.
[11] Dirk E. Smith,et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. , 2009, Arthritis and rheumatism.
[12] V. S. Wong. Kochar’s Clinical Medicine for Students , 2009 .
[13] Richard T. Lee,et al. The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.